華恆生物(688639.SH)2022年度扣非淨利潤預增96.12%至113.32%
格隆匯1月29日丨華恆生物(688639.SH)公佈,預計2022年度實現歸屬於母公司所有者的淨利潤為3億元至3.25億元,與上年同期相比,增加13176.45萬元至15676.45萬元,同比增加78.32%至93.18%;
預計2022年度實現歸屬於母公司所有者的扣除非經常性損益的淨利潤為2.85億元至3.1億元,與上年同期相比,增加13967.76萬元至16467.76萬元,同比增加96.12%至113.32%。
2022年,公司募集資金投資項目“發酵法丙氨酸5000噸/年技改擴產項目”和“交替年產2.5萬噸丙氨酸、纈氨酸項目”順利投產,產能逐步釋放,產品毛利率亦有所提升,公司盈利能力不斷增強。
2022年,公司緊緊圍繞發展戰略和年度經營目標,堅持“強組織、開新局、拉增長”的年度管理方針,積極面對市場需求及競爭形勢的變化,夯實組織管理能力,提升企業整體競爭力,進一步鞏固了市場競爭優勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.